A

References

Arrowsmith, J. 2011a. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10(5):328-329.

Arrowsmith, J. 2011b. Trial watch: Phase III and submission failures: 2007-2010. Nat Rev Drug Discov 10(2):87.

Baker, D., D. Butler, B. J. Scallon, J. K. O’Neill, J. L. Turk, and M. Feldmann. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24(9):2040-2048.

Bakker, A., C. B. Kirwan, M. Miller, and C. E. Stark. 2008. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science 319(5870):1640-1642.

Bakker, A., G. L. Krauss, M. S. Albert, C. L. Speck, L. R. Jones, C. E. Stark, M. A. Yassa, S. S. Bassett, A. L. Shelton, and M. Gallagher. 2012. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74(3):467-474.

Berer, K., M. Mues, M. Koutrolos, Z. A. Rasbi, M. Boziki, C. Johner, H. Wekerle, and G. Krishnamoorthy. 2011. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479(7374):538-541.

Braff, D. L, M. A. Geyer, and N. R. Swerdlow. 2001. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156(2-3):234-258.

Carter, R. J., L. A. Lione, T. Humby, L. Mangiarini, A. Mahal, G. P. Bates, S. B. Dunnett, and A. J. Morton. 1999. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19(8):3248-3257.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 77
A References Arrowsmith, J. 2011a. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10(5):328-329. Arrowsmith, J. 2011b. Trial watch: Phase III and submission failures: 2007- 2010. Nat Rev Drug Discov 10(2):87. Baker, D., D. Butler, B. J. Scallon, J. K. O’Neill, J. L. Turk, and M. Feldmann. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24(9):2040-2048. Bakker, A., C. B. Kirwan, M. Miller, and C. E. Stark. 2008. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science 319(5870):1640- 1642. Bakker, A., G. L. Krauss, M. S. Albert, C. L. Speck, L. R. Jones, C. E. Stark, M. A. Yassa, S. S. Bassett, A. L. Shelton, and M. Gallagher. 2012. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74(3):467-474. Berer, K., M. Mues, M. Koutrolos, Z. A. Rasbi, M. Boziki, C. Johner, H. Wekerle, and G. Krishnamoorthy. 2011. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479(7374):538-541. Braff, D. L, M. A. Geyer, and N. R. Swerdlow. 2001. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156(2-3):234-258. Carter, R. J., L. A. Lione, T. Humby, L. Mangiarini, A. Mahal, G. P. Bates, S. B. Dunnett, and A. J. Morton. 1999. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19(8):3248-3257. 77

OCR for page 77
78 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS Cissé, M., B. Halabisky, J. Harris, N. Devidze, D. B. Dubal, B. Sun, A. Orr, G. Lotz, D. H. Kim, P. Hamto, K. Ho, G. Q. Yu, and L. Mucke. 2011. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469(7328):47-52. Clozel, M. 2011. Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research. Sci Transl Med 3(67):67cm2. Conn, P. J., and B. L. Roth. 2008. Opportunities and challenges of psychiatric drug discovery: Roles for scientists in academic, industry, and government settings. Neuropsychopharm 33(9):2048-2060. Crabbe, J. C., D. Wahlsten, and B. C. Dudek. 1999. Genetics of mouse behavior: Interactions with laboratory environment. Science 284(5420):1670-1672. deIpolyi, A. R., K. P. Rankin, L. Mucke, B. L. Miller, and M. L. Gorno-Tempini. 2007. Spatial cognition and the human navigation network in AD and MCI. Neurology 69(10):986-997. Easterbook, P. J., J. A. Berlin, R. Gopalan, and D. R. Matthews. 1991. Publication bias in clinical research. Lancet 337(8746):867-872. Halliday, G.M. 2001. A review of the neuropathology of schizophrenia. Clin Exp Pharmacol 28(1-2):64-65. IOM (Institute of Medicine). 2010. Extending the spectrum of precompetitive collaboration in oncology research: Workshop summary. Washington, DC: The National Academies Press. Kaur, T., and K. S. Cadenhead. 2010. Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci 4:97-121. Kilkenny, C., W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman. 2010. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412. Kola, I., and J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711-715. Kramer, M. A. 1992. Autoassociative neural networks. Comp Chem Eng 16(4):313-328. Kumari, V., W. Soni, and T. Sharma. 1999. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156(7):1046-1051. Landis, S. C., S. G. Amara, K. Asadullah, C. P. Austin, R. Blumenstein, E. W. Bradley, R. G. Crystal, R. B. Darnell, R. J. Ferrante, H. Fillit, R. Finkelstein, M. Fisher, H. E. Gendelman, R. M. Golub, J. L. Goudreau, R. A. Gross, A. K. Gubitz, S. E. Hesterlee, D. W. Howells, J. Huguenard, K. Kelner, W. Koroshetz, D. Krainc, S. E. Lazic, M. S. Levine, M. R. Macleod, J. M. McCall, R. T. Moxley 3rd, K. Narasimhan, L. J. Noble, S. Perrin, J. D. Porter, O. Steward, E. Unger, U. Utz, and S. D. Silberberg. 2012. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490(7419):187-191.

OCR for page 77
APPENDIX A 79 Lenercept (The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group). 1999. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 53(3):457-565. Liu, J., M. W. Marino, G. Wong, D. Grail, A. Dunn, J. Bettadapura, A. J. Slavin, L. Old, and C. C. Bernard. 1998. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4(1):78-83. Mandillo, S., V. Tucci, S. M. Hölter, H. Meziane, M. A. Banchaabouchi, M. Kallnik, H. V. Lad, P. M. Nolan, A. M. Ouagazzal, E. L. Coghill, K. Gale, E. Golini, S. Jacquot, W. Krezel, A. Parker, F. Riet, I. Schneider, D. Marazziti, J. Auwerx, S. D. Brown, P. Chambon, N. Rosenthal, G. Tocchini-Valentini, and W. Wurst. 2008. Reliability, robustness, and reproducibility in mouse behavioral phenotyping: A cross-laboratory study. Physiol Genomics 34(3):243-255. Markou, A., C. Chiamulera, M. A. Geyer, M. Tricklebank, and T. Steckler. 2009. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology 34(1):74-89. Morgan, P., P. H. Van Der Graaf, J. Arrowsmith, D. E. Feltner, K. S. Drummond, C. D. Wegner, and S. D. Street. 2012. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17(9-10):419-424. Müssener, A., L. Klareskog, J. C. Lorentzen, and S. Kleinau. 1995. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis. Scand J Immunol 42(1):128- 134. Nicoll, J. A., E. Barton, D. Boche, J. W. Neal, I. Ferrer, P. Thompson, C. Vlachouli, D. Wilkinson, A. Bayer, D. Games, P. Seubert, D. Schenk, and C. Holmes. 2006. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65(11):1040-1048. Nieuwenhuis, S., B. U. Forstmann, and E. J. Wagenmakers. 2011. Erroneous analyses of interactions in neuroscience: a problem of significance. Nat Neurosci 14(9):1105-1107. NIH (National Institutes of Health). 2011. Quantitative and systems pharmacology in the post-genomic era: New approaches to discovering drugs and understanding therapeutic mechanisms. http://www.nigms.nih. gov/News/Reports/201110-syspharma.htm (accessed July 3, 2011). Nithianatharajah, J., N. H. Komiyanna, A. McKechanie, M. Johnstone, D. H. Blackwood, D. St. Clair, R. D. Emes, L. N. van de Lagemaat, L. M. Saksida, T. J. Bussey, and S. G. N. Grant. 2013. Synaptic scaffold evolution generated components of vertebrate cognitive complexity. Nature Neurosci 16(1):16-24.

OCR for page 77
80 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS Paul, S. M., D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg, and A. L. Schacht. 2010. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203-214. Prinz, F., T. Schlange, and K. Asadullah. 2011. Believe it or not: How much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10(9):712. Putcha, D., M. Brickhouse, K. O’Keefe, C. Sullivan, D. Rentz, G. Marshall, B. Dickerson, and R. Sperling. 2011. Hippocampal hyperactivation associated with cortical thinning in Alzheimer’s disease signature regions in non- demented elderly adults. J Neurosci 31(48):17680-17688. Rabchevsky, A. G., J. D. Degos, and P. A. Dreyfus. 1999. Peripheral injections of Freund’s adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res 832(1-2):84- 96. Richter, S. H., J. P. Garner, C. Auer, J. Kunert, and H. Würbel. 2010. Systematic variation improves reproducibility of animal experiments. Nat Methods 7(3):167-168. Rivers, T. M., D. H. Sprunt, and G. P. Berry. 1933. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58(1):39-53. Rogawski, M. A., and H. J. Federoff. 2011. Disclosure of clinical trial results when product development is abandoned. Sci Transl Med 3(102):102cm29. Romberg, C., M. P. Mattson, M. R. Mughal, T. J. Bussey, and L. M. Saksida. 2011. Impaired attention in the 3xTgAD mouse model of Alzheimer’s disease: Rescue by donepezil (Aricept). J Neurosci 31(9):3500-3507. Sarter, M., and M. Tricklebank. 2012. Revitalizing psychiatric drug discovery. Nat Reviews 11:423-424. Schenk, D., R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, and P. Seubert. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173-177. Schulz, K. F., D. G. Altman, and D. Moher, for the CONSORT Group. 2010. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials. BMJ (340):697-702. Scott, S., J. E. Kranz, J. Cole, J. M. Lincecum, K. Thompson, N. Kelly, A. Bostrom, J. Theodoss, B. M. Al-Nakhala, F. G. Vieira, J. Ramasubbu, and J. A. Heywood. 2008. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9(1):4-15. Sena, E. S., H. B. van der Worp, P. M. W. Bath, D. W. Howells, and M. R. Macleod. 2010. Publication bias in reports of animal stroke studies lead to major overstatement of efficacy. PLoS Biol 8(3):e1000344.

OCR for page 77
APPENDIX A 81 Sharief, M. K., and R. Hentges. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325(7):467-472. Shineman, D. W., G. S. Basi, J. L. Bizon, C. A. Colton, B. D. Greenberg, B. A. Hollister, J. Lincecum, G. G. Leblanc, L. B. Lee, F. Luo, D. Morgan, I. Morse, L. M. Refolo, D. R. Riddell, K. Scearce-Levie, P. Sweeney, J. Yrjänheikki, and H. M. Fillit. 2011. Accelerating drug discovery for Alzheimer’s disease: Best practices for preclinical animal studies. Alzheimers Res Ther 3(5):28. Steinman, L. 2003. Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. J Exp Med 197(9):1065-1071. Steinman, L., J. T. Merrill, I. B. McInnes, and M. Peakman. 2012. Optimization of current and future therapy for autoimmune diseases. Nat Med 18(1):59- 65. Swerdlow, N. R., and M. A. Geyer. 1993. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacology Biochemistry and Behavior 44(3):741-744. Swerdlow, N. R., J. Paulsen, D. L. Braff, N. Butters, M. A. Geyer, and M. R. Swenson. 1995. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 58(2):192-200. Swerdlow, N. R., D. L. Braff, and M. A. Geyer. 1999. Cross-species studies of sensorimotor gating of the startle reflex. Ann NY Acad Sci 87:202-216. Swerdlow, N. R., J. M. Shoemaker, S. Crain, J. Goins, K. Onozuka, and P. P. Auerbach. 2004. Sensitivity to drug effects on prepulse inhibition in inbred and outbred rat strains. Pharmacol Biochem Behav 77(2):291-302. Swerdlow, N. R., M. Weber, Y. Qu, G. A. Light, and D. L. Braff. 2008. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharm 199(3):331-388. Swinney, D. C., and J. Anthony. 2011. How were new medicines discovered? Nat Rev Drug Discov 10(7):507-519. ter Riet, G., D. A. Korevaar, M. Leenaars, P. J. Stark, G. J. F. Van Noorden, L. M. Bouter, R. Lutter, R. P. Oude Elferink, and L. Hooft. 2012. Publication bias in laboratory animal research: A survey on magnitude, drivers, consequence and potential solutions. PLoS ONE 7(9):e43404. Uher, R., K. E. Tansey, K. Malki, and R. H. Perlis. 2012. Biomarkers predicting treatment outcome in depression: What is clinically significant? Pharmacogenomics 13(2):233-240. van der Worp, H. B., D. W. Howells, E. S. Sena, M. J. Porritt, S. Rewell, V. O’Collins, and M. R. Macleod. 2010. Can animal models of disease reliably inform human studies? PLoS Med 7(3):e1000245.

OCR for page 77
82 ANIMAL MODELS FOR NERVOUS SYSTEM DISORDERS van Oosten, B. W., F. Barkhof, L. Truyen, J. B. Boringa, F. W. Bertelsmann, B. M. von Blomberg, J. N. Woody, H. P. Hartung, and C. H. Polman. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47(6):1531-1534. Verret, L., E. O. Mann, G. B. Hang, A. M. Barth, I. Cobos, K. Ho, N. Devidze, E. Masliah, A. C. Kreitzer, I. Mody, L. Mucke, and J. J. Palop. 2012. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149(3):708-721. Wang, S. J., H. M. Hung, and R. O’Neill. 2011. Adaptive design clinical trials and trial logistics models in CNS drug development. Eur Neuropsychopharmacol 21(2):159-166. Wilson, I., S. Ikonen, R. McMahan, M. Gallagher, H. Eichenbaum, and H. Tamila. 2003. Place cell rigidity is associated with poor spatial learning in aged rats. Neurobio Aging 24:297-305. Yassa, M. A., S. M. Stark, A. Bakker, M. S. Albert, M. Gallagher, and C. E. Stark. 2010. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic Mild Cognitive Impairment. Neuroimage 51(3):1242-1252.